ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. The partnership hopes to combine ERS’s CRISPR/Cas9 patent portfolio with MDC’s expertise and technology. As part of the deal, MDC and its partners will benefit from access to ERS’ CRISPR/Cas9 portfolio – the foundational CRISPR/Cas9 intellectual property held by […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
